PO.MCB01.01 · 分子与细胞生物学

Serpine2通过调控DDX3X/MITF/p21信号通路促进黑色素瘤进展

Serpine2 promotes melanoma progression through the modulation of the DDX3X/MITF/p21 signaling pathway

海报缩略图:Serpine2通过调控DDX3X/MITF/p21信号通路促进黑色素瘤进展
编号 1915 展板 23 时间 4/20 09:00–12:00 区域 Section 20 主讲 Jian Zhang, MD;PhD
分会场 Cell Cycle
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Qirui Liu1, Xin Huang1, Xiao Zhang2, Xinyu Ye1, Yi Lu1, Jian Zhang1

1School of Medicine, Southern University of Science and Technology, Shenzhen, China,2The Affiliated Foshan Hospital of Southern University of Science and Technology, Southern University of Science and Technology, Shenzhen, China

摘要 Abstract

中文摘要
黑色素瘤是最致命的皮肤癌,其特征为发病率不断上升和全球范围内的高死亡率。然而,黑色素瘤肿瘤发生和进展的潜在机制仍知之甚少。对公共数据库的分析已鉴定出SERPINE2是参与黑色素瘤相关生物学过程的一个关键差异表达基因。作为serpin超家族的成员,SERPINE2在调节蛋白水解活性、炎症和组织重塑方面发挥多种作用;然而,其在黑色素瘤中的具体功能有待进一步研究。本研究旨在探索SERPINE2影响黑色素瘤肿瘤发生和进展的潜在机制。在本研究中,我们通过分析来自TCGA、GTEx和TIMER2.0的数据评估了SERPINE2在黑色素瘤中的表达和临床相关性,并通过GO和KEGG富集分析鉴定了SERPINE2相关的生物学过程。我们的研究结果显示,与正常皮肤组织相比,SERPINE2在黑色素瘤组织中显著上调,且其表达与细胞生长、上皮-间质转化和免疫反应相关。敲低SERPINE2在体外和体内均显著抑制黑色素瘤细胞的活力、增殖和侵袭。对SERPINE2敲低细胞系的RNA测序分析表明,沉默SERPINE2可诱导细胞周期停滞于G0/G1期并促进凋亡。为研究其潜在机制,我们通过共免疫沉淀(CO-IP)和免疫沉淀-质谱(IP-MS)分析鉴定出DDX3X是SERPINE2的结合伴侣。我们发现SERPINE2会削弱DDX3X的蛋白稳定性,通过泛素-蛋白酶体系统促进其降解。此外,沉默DDX3X导致MITF和p21核蛋白表达下调,提示DDX3X下调可能影响与细胞周期进程相关的下游基因的转录,从而影响黑色素瘤生长。另外,下调SERPINE2增强了CD8+ T细胞浸润,刺激了T细胞活化相关的细胞因子和趋化因子,并在体外改善了CD8+ T细胞的细胞毒功能。此外,在Lauss队列和IMvigor210队列中,我们观察到SERPINE2表达与接受免疫治疗的黑色素瘤患者的预后相关;具体而言,与高SERPINE2表达患者相比,低SERPINE2表达患者表现出更好的预后。总之,SERPINE2的表达水平是黑色素瘤患者治疗反应和预后的预测指标,提示其作为黑色素瘤免疫治疗生物标志物的潜力。本研究得到中国国家自然科学基金(No. 82173336)和MRI项目(G030410001)的资助。
查看英文原文 English abstract
Melanoma is the most lethal form of skin cancer, characterized by an increasing incidence and high mortality rates globally. However, the mechanisms underlying melanoma tumorigenesis and progression remain poorly understood. Analyses of public repositories have identified SERPINE2 as a key differentially expressed gene involved in the biological processes associated with melanoma. As a member of the serpin superfamily, SERPINE2 plays diverse roles in regulating proteolytic activity, inflammation, and tissue remodeling; however, its specific functions in melanoma warrant further investigation. This study aims to explore the potential mechanisms by which SERPINE2 influences tumorigenesis and progression in melanoma. In this study, we evaluated the expression and clinical relevance of SERPINE2 in melanoma by analyzing data from TCGA, GTEx, and TIMER2.0, and identified SERPINE2-associated biological processes through GO and KEGG enrichment analyses. Our findings revealed that SERPINE2 is significantly upregulated in melanoma tissues compared to normal skin tissues, and its expression correlates with cell growth, epithelial-mesenchymal transition, and immune response. Knockdown of SERPINE2 markedly inhibited cell viability, proliferation, and invasion of melanoma cells both in vitro and in vivo . RNA sequencing analysis of SERPINE2-knockdown cell lines demonstrated that silencing SERPINE2 induced cell cycle arrest in the G0/G1 phase and promoted apoptosis. To investigate the underlying mechanisms, we identified DDX3X as a binding partner of SERPINE2 through co-immunoprecipitation (CO-IP) and immunoprecipitation-mass spectrometry (IP-MS) analyses. We found that SERPINE2 attenuates the protein stability of DDX3X, promoting its degradation via the ubiquitin-proteasome system. Furthermore, silencing DDX3X resulted in the downregulation of nuclear protein expression of MITF and p21, suggesting that DDX3X downregulation may influence the transcription of downstream genes associated with cell cycle progression, thereby impacting melanoma growth. Additionally, downregulation of SERPINE2 enhanced CD8+ T cell infiltration, stimulated T-cell activation-related cytokines and chemokines, and improved the cytotoxic function of CD8+ T cells in vitro . Furthermore, in both the Lauss cohort and the IMvigor210 cohort, we observed that SERPINE2 expression correlated with the prognosis of melanoma patients undergoing immunotherapy; specifically, patients with low SERPINE2 expression exhibited better prognoses compared to those with high SERPINE2 expression. In summary, the expression level of SERPINE2 is a predictor of therapy response and prognosis in melanoma patients, suggesting its potential as a biomarker for melanoma immunotherapy. This work was supported by the National Natural Science Foundation of China (No. 82173336), and the MRI Project (G030410001).
利益披露 Disclosure
Q. Liu, None.. X. Huang, None.. X. Zhang, None.. X. Ye, None.. Y. Lu, None.. J. Zhang, None.

← 返回 AACR 2026 检索